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numerous monoclonal antibodies have been developed successfully for the treatment of various 
diseases. Nevertheless, the development of biotherapeutic antibodies is complex, expensive, and 
time‑consuming, and to facilitate this process, careful structural analysis beyond the antibody binding 
site is required to develop a more efficacious antibody. In this work, we focused on protein antigens, 
since they induce the largest antibody changes, and provide interesting cases to compare and 
contrast. The structures of 15 anti‑protein antibodies were analysed to compare the antigen‑bound/
unbound forms. Surprisingly, three different classes of binding‑induced changes were identified. 
In class (B1), the antigen binding fragment distorted significantly, and we found changes in the 
loop region of the heavy chain’s constant domain; this corresponds well with expected allosteric 
movements. In class (B2), we found changes in the same loop region without the overall distortion. In 
class (B3), these changes did not present, and only local changes at the complementarity determining 
regions were found. Consequently, structural analysis of antibodies is crucial for therapeutic 
development. Careful evaluation of allosteric movements must be undertaken to develop better 
effector responses, especially during the transformation of these antibodies from small fragments at 
the discovery stage to full antibodies at the subsequent development stages.
Diversity in the vertebrate immune system is a critical factor in the continuous protection against a plethora 
of invading pathogens. In this context, antibodies, which are produced by B-lymphocytes, play a pivotal role 
to neutralise these invading agents and eliminate them through different immunological mechanisms. This is 
evident in their ability to recognise various molecular signatures, ranging from proteins, peptides, nucleic acids, 
lipids, or small haptens with a molecular weight < 1,000 Da1.
An antibody is composed of two Fragment antigen binding (Fab) regions and one Fragment crystallisable 
(Fc)  region2,3. The Fab fragment is responsible for antigen recognition through its variable sites, while the Fc 
region can propagate a series of effector  responses4. The antigen recognition process is accomplished by the 
complementarity determining regions (CDRs) located at the tips of the Fabs, occasionally being supported by a 
few residues from the framework regions (highly conserved regions that are responsible for acting as a scaffold 
for the CDRs). In general, an antibody should discriminate between self-molecules (produced by an organism) 
and exogenous foreign antigens (like viruses and bacteria) to restrict its function against the external antigens, 
and demonstrate the required tolerance to self-antigens. The inability to distinguish between these interaction 
processes might explain several autoimmune diseases.
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The six CDRs comprise ~ 70 residues out of the ~ 230 amino acids in each chain of the Fab  fragment5, and 
form a continuous surface of approximately 2,800 Å26. Webster et al. initially correlated the binding sites surface 
topography to various antigen  types7. These shapes include pockets to accommodate small haptens, grooves to 
enclose peptides, and flat surfaces to grasp large protein  surfaces8. These surface arrangements were confirmed 
by measurements of the solvent accessible surface area, which were estimated to be 200–400 Å2, 400–600 Å2 
and ~ 800 Å2 for anti-haptens, anti-peptides, and anti-protein antibodies,  respectively9.
It is widely proposed that an antibody-antigen interaction can use either specific or nonspecific interfaces 
where the surfaces may mould to fit each other, following a “lock-and-key” or “hand-shake” (induced fit) format, 
respectively. The generated antibodies’ affinity is largely dependent on the number and type of amino acids that 
form the CDRs loops, and determine the binding site surface  topography10. The antigen-binding region (para-
tope) and the antigenic determinant (epitope) are held together by non-covalent forces, which also dictate the 
affinity of these  antibodies11. This interaction is also orchestrated by complementarity in the paratope-epitope 
charge and  shape1. Somatic gene-recombination and mutations, antibody class-switching, and heavy and light 
chain dimerisation, are mechanisms that can craft the malleable binding sites to accommodate a wide range of 
 antigens12–15.
Despite the significant interest of the biopharmaceutical industry in generating and crafting antibody binding 
sites with the highest affinity, it is equally crucial to understand the conformational changes beyond these binding 
sites. This will ensure successful and compatible transformation of small antibody fragments, such as single-chain 
variable fragment (scFv), single chain antibody fragments (scAbs), and Fabs, at the early developmental stages 
to full antibodies, without losing their high affinities or their effector functions. Consequently, understanding 
how the interaction of an antibody with its antigen propagates a signal to the Fc region (the allosteric model) is 
of critical importance to the engineering of antibodies and the development of new therapeutics.
In order to address the above question, we have analysed various Fab crystal structures of IgG antibodies, 
crystallised in free and antigen-complexed formats, that are available in the Protein Data Bank (PDB) (Table 1). 
Sela-Culang et al.16 reported that antibody binding to proteins induces larger conformational changes than 
binding to smaller peptides, associating this with an allosteric signalling response. Focusing on protein anti-
gens as a potential target-class for several biotherapeutic  programmes17, and by detailed inspection of available 
structures that are amenable to analysis, we have found that the allosteric mechanism proposed  in16 is not uni-
versally observed. While we could identify cases where the antigen binding induces a clear allosteric signalling 
pathway, we also found cases when the binding results only in local changes. The analysis will help clarify the 
type of structural change required for the antibody to achieve its desired properties when under development 
as a new therapeutic.
Results
Due to the large amount of data, only the most characteristic observations and conclusions are included in the 
manuscript while the entire data set supporting these, as well as further details of the analyses, can be found in 
Supplementary Materials.
Antibody domain orientation changes on antigen binding. Analysis of the heavy and light chain 
orientations of the anti-protein Fabs (Scheme 1) revealed high angle changes in four of the couples, as summa-
rised in Table 2 (full results are provided in the Supplementary Materials).
Based on these movements, three different classes of behaviour can be identified, denoted B1-3. In class 
B1, the binding results in large conformational changes that can be pictured as a changing aspect ratio of the 
diamond-like shape of the Fab. In particular, these changes in angle come from a reduction in the angle between 
the heavy chains and an increase in that between the light chains. The angle changes were additionally confirmed 
by corresponding distance changes between key cysteine residues on each domain (see Scheme 1). The linker-
linker distance of this B1 class has also increased in the bound form when compared to their free counterparts.
Table 1.  PDB couples examined in this work.
PDB couples Species Target Development
3G6A/3G6D Homo sapiens Interleukin 13 (IL-13) CNTO 607 (monoclonal antibody originally isolated from the Morpho-Sys phage display library HuCAL)
3HMW/3HMX Homo sapiens Interleukin 12 (IL-12) Ustekinumab or CNTO 1,275 (developed by Centocor, from transgenic mice using genetic engineering techniques)
3EO9/3EOA Homo sapiens Lymphocyte function-associated antigen 1 (LFA-1)I domain, Form I
Efalizumab (developed by Genentech/Xoma, as a humanized antibody 
produced in a Chinese hamster ovary mammalian cell expression 
system)
3EO9/3EOB Homo sapiens Lymphocyte function-associated antigen 1 (LFA-1) I domain, Form II As above
1MLB/1MLC Mus musculus Chicken egg-white lysozyme D44.1 (Mouse monoclonal antibody)
1DQQ/1DQJ Mus musculus Hen egg white lysozyme HYHEL-63 (Mouse monoclonal antibody)
5BVJ/5BVP Homo sapiens Interleukin 1 beta (IL-1β)
Canakinumab or ACZ885 (fully human antibody developed by 
Novartis, through UltiMab technology (Medarex) using transgenic 
mice)
2FJF/2FJG Homo sapiens Vascular endothelial growth factor (VEGF) Synthetic antibody phage libraries
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In contrast, the other two classes of behaviour (B2 and B3 in Table 2) show relatively small changes to the 
angles. The distinction between B2 and B3 will be explained in the following sections.
Conformational changes and root‑mean‑square‑deviation (RMSD). The conformational changes 
were determined by calculating the total RMSD between the antibody-antigen complex and the antibody-free 
counterparts. This is obtained from the optimal overlap of the entire Fab. From these overlapped structures, the 
RMSD can also be calculated for each domain (note that the individual domains are not separately optimised 
here). As summarised in Table 3, all the anti-protein couples showed more overall movement upon binding in 
the heavy chains. In addition, the constant domains  (CH and  CL) of these Fabs tend to have bigger RMSD values 
than the variable domains  (VH and  VL). The shape of the antibody binding surface can be optimised through 
movements of the constant domains relative to the variable domains and to each other to generate a suitable 
 VH-VL relative  orientation18–20.
The high movement of constant domains might also be correlated with signal propagation. We noticed these 
movements through analysis of an entire antibody in molecular dynamics  simulations21. These movements are 
logically expected to be more in the heavy chain when compared to light chains, since the Fab-to-Fc allosteric 
movements occur in these heavy chains and through the main Fab-Fc linker. We explore prospective allosteric 
movements in the following section.
Scheme 1.  Angle measurements. The IgG antibody can be dissected into three fragments: two identical 
antigen-binding fragments (Fabs) that each contain the first two domains of the heavy  (VH and  CH1) and light 
 (VL and  CL) chains, and one crystallisable region fragment (Fc) consisting of two monomers, each comprising 
 CH2 and  CH3 domains. The amplified Fab region illustrates the amino acid positions used to calculate the domain 
orientational changes. The selected amino acids are denoted as C: cysteine, S: serine, Q: glutamine (in λ light 
chains), and R: arginine (in kappa light chains).
Table 2.  Binding conformational change classes.
PDB structures Magnitude of average change in angle Class for binding conformational change
3G6A/3G6D 37° B1
3HMW/3HMX 16° B1
3EO9/3EOA 25° B1
3EO9/3EOB 25° B1
1MLB/1MLC 4° B2
1DQQ/1DQJ 4° B2
5BVJ/5BVP 2° B2
2FJF/2FJG 3° B3
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Conformational changes and root‑mean‑square‑fluctuations (RMSF). The RMSF, reporting 
deviations in the backbone position of each residue between the free and antigen bound antibodies, are reported 
in Fig. 1. Each of the binding conformational change categories from Table 2 is illustrated by one couple. In 
Fig. 1, we show the RMSF for the entire heavy (light) chain obtained from its optimal overall. We also show the 
RMSF calculated for each domain, using the optimal overlap of each domain separately. In this way we are able 
to distinguish which parts of the structure change and in what way. To obtain the data presented in Fig. 1, two 
crystal structures were compared: one as a free antibody and the second as an antibody/antigen complex. The 
RMSF was analysed for each amino acid position in the two compared crystal structures. This comparison was 
performed on the total chain (heavy and light) and independently on their specific domains (VH, CH, VL, and 
CL). The x-axis in Fig. 1 represents the amino acid positions of either the heavy or light chain running from the 
N- to C-terminus, allowing them to be compared on the same figure. Heavy chain loops are highlighted in grey 
and light chain loops are highlighted in yellow. The three loops in the variable domains are named CDR1-3, 
and he three loops in the constant domains (CH and CL) are named C_Loop1-3, according to their location 
throughout the sequence from the N-terminal to the C-terminal of the entire chain. These six loops were respec-
tively shaded as grey and yellow for the heavy and light chains.
The top panel in Fig. 1 shows the RMSF for the 3G6A/3G6D couple in class B1. Both the heavy and light 
chains display significant RMSF values across the Fab sequence, dominated by the large conformational changes 
reported in Table 2 (recall that these RMSF are calculated from the optimal overlaps of the full chains between 
the structures in the couple). The loop structure of the heavy and light chains along their sequences is reflected 
in the RMSF pattern as might be expected. We also show the RMSF calculated from the optimal overlap of each 
domain separately. These RMSF values tend to be much lower, demonstrating a hinge-like movement between 
fairly rigid domains induced by the antigen adsorption. This is in line with the analysis of the angular changes 
between the domains in the Fab reported above.
The  CH1 domain of class B1 by itself also displays large RMSF values in the region of the C_Loop1, as well as 
movements in its CDRs. The latter could be attributed to the binding between the antibody and antigen, while the 
former is probably associated with an allosteric signal propagation to the Fc region. As seen in the Supplementary 
Materials, the other couples in the B1 class (Table 2) also display very similar behaviour, with large RMSF overall 
and the CH domain displaying large values in the vicinity of the C_Loop1 and CDR3.
Figure 2 illustrates the relative domain conformational changes induced in category B1. The overlap between 
3G6A and 3G6D are shown in cartoon representation to clarify the changes to the diamond-like Fab structure 
when the antigen protein binds in the vicinity of the groove between the VL and VH domains (the left panel in 
Fig. 2 illustrates the binding configuration, with the right panel showing the overlaps). It seems intuitive that this 
distortion of the Fab conformation will allow better interaction between the antigen and antibody, permitting 
more inter-residue interactions between the biomolecules.
Returning to Fig. 1, the middle panel shows the RMSF results for an exemplar of class B2 for binding con-
formational changes. In contrast to B1, in the B2 class we did not find large wholesale RMSF values when we 
overlapped the light and heavy chains in their entirety, because there are no large relative orientational changes 
to the domains (see Table 2). In other words, the diamond-like structure of the Fab remains largely unchanged 
upon binding with the antigen in this category (Fig. 3). Surprisingly, however, we did find that there is again a 
large change in the C_Loop1 region of the CH domain. Again, this might indicate a possible allosteric change 
propagated to the Fc region of the antibody. This behaviour is replicated in the other couples in the B2 category 
(see Supplementary Materials), along with varying degree of change to the CDR regions induced by the antigen 
binding. The change in the C_Loop1 region of the 5BVP structure is illustrated in Fig. 3.
Finally, we discuss the 2FJF/2FJG couple from class B3 (Fig. 4). Unlike the previous examples, this antibody 
shows no significant change in the C_Loop1 region upon binding to its target (Fig. 1). Instead, we see a very 
strong change occurring at the binding site only, with prominent changes in the VH domain at CDR2 and to 
a lesser extent at CDR3; no other large scale alterations to the Fab structure are observed. Close-up views of 
the changes at the CDRs are illustrated in Fig. 4. This different behaviour suggests that this antibody does not 
require an allosteric signal propagation. Indeed, it is a phage-derived antibody from a synthetic library rather 
than a naturally occurring antibody (Table 1), and it would seem that while it is selected for its binding affinity, 
its inability to propagate an allosteric signal upon binding has not been part of the selection process.
Table 3.  Trends in RMSD. The RMSD values of all PDB structures analysed here are listed in Supplementary 
Table S1.2.
Light chain > heavy chain None
Light chain < heavy chain All 8 couples
Light chain
CL < VL
2FJF/2FJG
3EOA/3EO9
3EOB/3EO9
CL > VL Remaining 5 couples
Heavy chain
CH < VH 2FJF/2FJG
CH > VH Remaining 7 couples
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This movement in CDR-H2 was observed by the researchers who crystalised 2FJF and 2FJG, and was attrib-
uted to the adoption of a highly unusual and non-canonical conformation of CDR-H2 following the antigen 
 binding23. This was caused by a tight packing of CDR-H2 against CDR-H1 and a section of the antibody that is 
part of the framework 3 region. This drastic conformational change of CDR-H2 was facilitated by three glycines 
at positions 50, 54, and 55, which are likely to provide CDR-H2 the flexibility required to show such a signifi-
cant conformational change. In contrast, the same authors found CDR-H2 of the free antibody (2FJF) is in a 
very different position and packs against CDR-L3 and CDR-H3, following the commonly observed canonical 
Figure 1.  RMSF to illustrate the three antigen binding classifications reported in Table 2. (A) 3G6A/3G6D from 
class B1; (B) 5BVP/5BVJ from class B2; and (C) 2FJF/2FJG from class B3.
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Figure 2.  Category B1 conformational changes observed in 3G6A/3G6D, using VMD 1.9.322. (A) Illustrates 
the bound configuration of the antigen–antibody with the heavy chain in blue and light chain in green, and the 
antigen white. (B) Displays the structural overlap of the entire Fab between the bound (blue/green) and free 
(red/yellow) structures.
Figure 3.  B2 Conformational changes—focus on the C_Loop1 heavy chain movement in 5BVP/5BVJ, using 
VMD 1.9.322. This figure illustrates the deviation in C_Loop1 between the bound versus the free form of the 
Fabs (5BVP/5BVJ).
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conformation. The high movement of CDR-H2 of 2FJG when compared to 2FJF was observed in our RMSD 
analysis of this pair, as demonstrated in Fig. 1C.
Discussion and conclusions
We have shown how straight-forward analyses of crystal structures can help identify possible allosteric signal-
ling pathways caused by antibody-protein antigen binding. The analyses focus on backbone structural changes, 
and avoid the necessity for expensive simulations. The assumption is made that the crystal contacts in the PDB 
structures do not strongly affect the backbone structure; this assumption can be explored further in future work.
In this work, we have compared the crystallised Fab structures of 8 couples, each of which has a free IgG 
antibody and the same antibody bound to its protein antigen target. In so doing, we identify three classes of 
behaviour:
B1: The binding causes a deformation of the diamond-like Fab structure, with the four domains  (VH,  VL,  CH1 
and  CL) maintaining their individual structures but changing relative orientation by hinging at the linker 
regions between them. This category displays a further prominent change in the  C_Loop1 region indicating 
an allosteric signal propagation.
B2: The binding does not deform the overall diamond-like Fab structure, but still shows the prominent 
 C_Loop1 deformation as in B1.
B3: The binding only causes changes at the CDR regions directly interacting with the antigen, and no obvious 
allosteric signalling pathway is apparent.
The class B3 results were surprising, however, it is based on only one protein antigen example, and this is derived 
from a phage display for its binding affinity. Nevertheless, it holds a cautionary lesson for the development of 
therapeutics from small antibody fragments; it is not sufficient to optimise binding locally at the CDRs if ulti-
mately one requires an Fc effector response to be initiated by the binding to the antigen. In fact, we identified 
more antibodies of class B3, which were developed against hapten-antigens.
Our results for class B1 and B2 are in line with observations made elsewhere. Sela-Culang et al.16 showed that 
 C_Loop1 is the highest moving loop, deviating even more than CDRH3 when binding the antigen. Various other 
studies have correlated the  CH1 domain to changes in binding, because it was recognised as the only region with 
sequence diversity between the antibodies being  examined22–24. It has been suggested that the  C_Loop1, linking 
the heavy and light chains, is intrinsically disordered and involved in complement  binding16. Furthermore, the 
 C_Loop1 is part of the interface with the  CL domain, and occasionally connected to the  CL domain through a 
disulphide bond, thereby having a potential effect on the  CH1-CL relative orientation. Moreover, this loop is close 
to the main hinge region, and a conformational change in this loop may affect the relative orientation of the  CH1 
domain versus the entire Fc, thus influencing the overall effector function of the Fc  region17,25. Therefore, this 
loop can be highly prone to movement to fulfil the required structural changes upon binding.
Figure 4.  Category B3 conformational changes observed in 2FJF/2FJG, using VMD 1.9.322. (A) Illustrates the 
binding surface of the antibody along with the CDRs distribution across the surface. (B) displays the CDRs 
alignment comparison between the bound (blue/green) and free (red/yellow) structures. The CDRs are shown 
in white, with the bound structures thinner that the unbound ones for clarity of comparison.
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The higher movements of the constant domains compared to the variable domains observed in B1 (and to 
some extent in B2) have been discussed elsewhere with regard to antigen binding affinity. For instance, two 
human monoclonal antibodies having similar variable domains, but different constant domains, were shown 
to bind their target with significantly different  affinities22. Furthermore, comparing the binding affinity of Fabs 
to smaller versions of variable fragments (Fv) have also revealed a large difference in  affinity26. In fact, the 
binding epitopes of two anti-HIV1  IgG1 and  IgA2 antibodies with identical variable domains are only partially 
 overlapping27. Similarly, analysis of trastuzumab, crenezumab, and pertuzumab recombinant models have sug-
gested that antibodies with the same variable domains, but different constant domains, have significantly different 
antigen binding and  affinity28,29.
In summary, the binding of antibodies to their protein antigens can induce strong structural deformations 
that can propagate through the heavy chain to the Fc regions, potentially triggering an effector response, and in 
this the  CH domain and its C_Loop1 plays a prominent role. In addition, changes in the constant domains can 
also be important to the antigen affinity. However, antigen binding does not universally induce these effects, and 
this implies that careful assessment of binding-induced structural changes must be undertaken when developing 
new therapeutics.
Methods
Antibody selection. The structures of Fabs from several IgG antibodies, crystallised as both free and anti-
gen protein-complexed formats and reported in the same articles, were retrieved from the PDB. Only struc-
tures with acceptable resolution (< ~ 3 Å) were included in the analysis to allow a confident determination of 
the molecular interactions and  structures9,30,31. A total of 15 crystal PDB structures against protein antigens 
(4 mouse and 11 full human) were identified and selected (Supplementary Table S1.1). Free antibody struc-
tures were considered similar if their chains (heavy and light) shared 100% sequence identity, and have similar 
sequence to the antigen bound form. For instance, one crystal structure (PDB entry 2FJF) contains 12 Fabs in 
the asymmetric unit to form a single dodecameric complex. We have selected one Fab of the antibody free form 
to be compared with the antigen bound form (PDB entry 2AJG), since the authors of the PDB entry report that 
these 12 structures share the same crucial  features23. Similarly, with other cases of multiple structures in the PDB 
entry, we select one on the understanding that the other structures are the same in all essential features.
While preparing the retrieved PDB files, all amino acid positions were sequentially numbered to avoid missing 
or duplicating residue positions, and to ensure that calculations to compare structures gave correct measure-
ments. A few sequences (5GGV, 5GGU, 3NFP and 3NFS) were omitted from the study due to the fact that the 
reported polypeptide chains were not continuous, so that the remaining 15 structures studied allowed detailed 
analyses.
The selected structures were organised into 8 couples as detailed in Table 1, and for each couple, two crystal 
structures were compared: one for the free antibody and the second for the antibody/antigen complex. The analy-
ses included: alignment of the CDRs; alignment of the two crystal structures to compare deviation in the antigen 
binding areas; quantification of the deviation between the structures overall, by light and heavy chain conserved 
and variable regions, and on an individual amino acid basis; and quantification of the relative orientation of the 
heavy and light domains. The three loops in the variable domains were denoted CDRs 1–3, and the three loops 
in the constant domains (CH and CL) were named C_Loop 1–3, according to their location throughout the 
sequence from the N-terminal to the C-terminal of the entire chain.
The PDB Fab sequences were retrieved and analysed using BioEdit Sequence Alignment Editor, version 7.2.532. 
ClustalW Multiple alignment was used to align sequences of the same type (heavy or light chains) and origin 
(human or mouse). All the gathered and analysed sequences are listed in Supplementary Table S3.1–S3.5. The 
six CDRs of the Fab fragments were defined using the Kabat numbering  system33.
Note that in our analyses, we assume that the crystal contacts in the PDB structures will have negligible effects 
on results. This is justified, because we analyse structural changes in terms of backbone movements rather than 
side-chains, which are most likely affected by crystal formation.
RMSD and RMSf. RMSD is a commonly used tool that quantifies the structural overlap of protein struc-
tures, such as different conformations of the same  protein34. For this study, the RMSD is defined as
where N is the number of (backbone) atoms in the protein structure and ri,A , ri,F is the position of the i-th atom in 
the antigen-bound (A) and free (F) Fab structure. In practice, to calculate the RMSD, the two protein structures 
to be compared are initially treated as rigid bodies that are overlapped (aligned) using only translations and 
rotations. The RMSDs of the backbone atoms only were calculated for each couple for the entire antibody chain 
(residues 1–218) as well as particular regions, namely: variable (residues 1–105), linker (106–113) and constant 
(114–218) domains. The side chains of the residues were excluded from the RMSD calculations, since differences 
in their orientations could introduce additional noise. Moreover, we are interested in global structural changes, 
not the local alterations in side chain orientation.
Another beneficial tool to track structural changes in proteins is denoted RMSF, where the RMSD is calculated 
and reported for each residue in the compared structure. It is regularly referred to as “fluctuation” because it 
measures an amplitude of residue movement (fluctuation) from the compared position in the aligned structures. 
Although usually measured for dynamic structures, for static structures it provides the local RMSD calculated 
for each residue. Therefore, the traditional RMSD gives one number reflecting the average difference between 
(1)RMSD =
√∑
N
i=1
∣∣�ri,A − �ri,F ∣∣2
N
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the entire protein chains being compared, while RMSF “divides” this difference and reports it per residue. 
Consequently, it is easy to track the residues (and so sequence parts) which do not change conformation and 
the residues (sequence parts) which are the most responsible for the observed conformational alterations upon 
antigen binding. The RMSDs are calculated using the  VMD35 built-in tool while RMSFs are calculated using a 
Tcl script executed from the VMD Tk console. The unit for both is Å  (10−10 m).
Variable and constant domain orientation. The relative orientation of the variable heavy and light 
 (VH and  VL) versus conserved heavy and light  (CH1 and  CL) domains was quantified to complement the RMSD/
RMSF analyses. One conserved cysteine residue (Cys) was selected in each of the  VL,  CL,  VH, and  CH1 domains 
(Scheme 1). In addition, one conserved amino acid in each of the  VL/CL and  VH/CH1 linkers was also selected; 
these are Serine (Ser), Arginine (Arg), and Glutamine (Gln) in the heavy, light (K), and light (λ) chains, respec-
tively (Scheme 1). The six amino acids thus selected in each Fab are highlighted in turquoise in the full sequence 
file (Supplementary S3). The angles of the heavy (C-S-C) and light (C-Q-C or C-R-C) chains were measured by 
PyMOL (The PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC.) and confirmed by  VMD35. 
The distances from the two Cys residues in the heavy and light chains were additionally measured by PyMOL 
and VMD.
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